Loading...
Comparative outcomes of budesonide mmx versus prednisolone for ulcerative colitis: Results from a British retrospective multi‐centre real‐world study
Rosiou, K Ong Ming San, E Kumar, Aditi Esquivel, Kim Almas, Saima Stokes, Daniel Ng, Tze Jayasooriya, Nishani Ranasinghe, Ian Pollok, Richard
Rosiou, K
Ong Ming San, E
Kumar, Aditi
Esquivel, Kim
Almas, Saima
Stokes, Daniel
Ng, Tze
Jayasooriya, Nishani
Ranasinghe, Ian
Pollok, Richard
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2021-09-23
Submitted date
Alternative
Abstract
During the COVID‐19 pandemic many IBD units chose Budesonide MMX (Cortiment) as the first‐line treatment for flares of ulcerative colitis (UC) in outpatients for its favourable side effect profile. This retrospective study of all UC patients treated with oral steroids between 1 March 2019– 30 June 2019 and 1 March 2020–30 June 2020 aimed to compare Cortiment with Prednisolone in routine clinical practice. Outcomes included the need for hospitalisation for acute severe ulcerative colitis, symptoms at four weeks and end of treatment, and the need for rescue Prednisolone. The 2019 and 2020 cohorts did not differ at the baseline. Cortiment prescriptions rose from 24.5% in 2019 to 70.1% in 2020 (p < 0.001). At week four there were significant differences between 2019 and 2020 in mean bowel frequency (3.49 vs. 5.85, p = 0.001), rectal bleeding <50% (89.7% vs. 73.1% of patients, p = 0.039), and physician global assessment (PGA) (39.2% vs. 19.8% in remission, p = 0.045). There was no significant difference in hospital admissions, rectal bleeding, and PGA at week eight. Rescue Prednisolone was required in 10% of Cortiment patients in 2019 vs. 31.3% in 2020 (p = 0.058). Active IBD is associated with worse COVID‐19 outcomes prompting the careful evaluation of the choice of first‐line steroid for UC, as Cortiment was associated with worse outcomes at four weeks.
Citation
Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. (2021) Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. Journal of Clinical Medicine, 10(19):4329. https://doi.org/10.3390/jcm10194329
Publisher
Journal
Research Unit
PubMed ID
34640345 (pubmed)
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en
Description
© 2021 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/jcm10194329
Series/Report no.
ISSN
2077-0383
EISSN
2077-0383
ISBN
ISMN
Gov't Doc #
Sponsors
Rights
Licence for published version: Creative Commons Attribution 4.0 International